Pharmacodynamics of rituximab in kidney allotransplantation

American Journal of Transplantation

Volumn 6, Issue 10, 2006, Pages 2418-2428

  Genberg, H ^a   Hansson, A ^a   Wernerson, A ^a   Wennberg, L ^a   Tyden G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Graft infiltrating lymphocytes; Immunoglobulin; Immunosuppression; Kidney transplantation; Lymph node

Indexed keywords

AZATHIOPRINE; CD20 ANTIBODY; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ALLOTRANSPLANTATION; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT; KIDNEY PARENCHYMA; LYMPH NODE; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; ANTIGENS, CD20; B-LYMPHOCYTES; BIOPSY; CHILD; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; LYMPH NODES; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33748515952     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01497.x     Document Type: Article

References (25)

1. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
2. Tsokos GC. B cells, be gone - B-cell depletion in the treatment of rheumatoid arthritis. N Engl J Med 2004; 350: 2546-2548.
3. Tydén G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003; 76: 730-731.
4. Sonnenday CJ, Warren DS, Cooper M et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow AB0-incomaptible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1316-1322.
5. Tydén G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. AB0 incompatible kidney transplantation without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145-148.
6. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001.
7. Sidner RA, Book BK, Agarwal A, Bearden CM, Viera CA, Pescovitz MD. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 2004; 13: 55-62.
8. Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542-548.
9. Deneys V, Mazzon AM, Marques JL, Benoit H, de Bryère M. Reference values for peripheral blood B-lymphocyte subpopulations: A basis for multiparameteric immunophenotyping of abnormal lymphocytes. J Immunol Methods 2001; 253: 23-36.
10. Chu PG, Arber DA. CD79: A review. Appl Immunohistochem Mol Morphol 2001; 9: 97-106.
11. Racusen L, Solez K, Colvin RB et al. The Banff 97 working classification of kidney allograft pathology. Kidney Int 1999; 55: 713-723.
12. Racusen L, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to Banff' 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
13. Bryan CF, Eastman PJ, Conner JB, Baier KA, Durham JB. Clinical utility of a lymph node normal range obtained by flow cytometry. Ann NY Acad Sci 1993; 677: 404-406.
14. Shröder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transplant Immunol 2003; 12: 19-28.
15. Fernández-Fresnedo G, Ramos MA, González-Pardo MC, Martín de Francisco AL, López-Hoyos M, Arias M. B lymphopenia in uraemia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrol Dial Transplant 2000; 15: 502-510.
16. Martín-Malo A, Carracedo J, Ramírez R, Rodriguez-Benot A, Soriano S, Rodriguez M, Aljama P. Effect of uremia and dialysis modality on mononuclear cell apoptosis. J Am Soc Nephrol 2000; 11: 936-942.
17. Catron G, Watier H, Golay J, Solal-Celigny P. From the bench to bedside: Ways to improve rituximab efficacy. Blood 2004; 104: 2635-2642.
18. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus. Arthritis Rheum 2004; 50: 2580-2589.
19. Polyak MJ, Deans JP. Alanine-170 and praline 172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002; 99: 3256-3262.
20. Cragg MS, Bayne MC, Illidge TM, Valerius T, Johnson PWN, Glennie MJ. Apparent modulation of CD20 by rituximab: An alternative explanation. Blood 2004; 10: 3989-3990.
21. Janeway CA Jr, Ron J, Katz ME. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol 1987: 138: 1051-1055.
22. Rasetter W, Molina A, White CA. Rituximab: Expanding role in therapy for lymphomas and autimmune diseases. Annu Rev Med 2004; 55: 477-503.
23. Hippen BJ, DeMattos A, Cook WJ, Kew CE II, Gaston RS. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 2005; 5: 2248-2252.
24. Steinmetz OM, Panzer U, Kneissler U et al. BCA-1/CXCL13 expression is associated with CXCR5-positive B-cell cluster formation in acute renal transplant rejection. Kidney Int 2005; 67: 1616-1621.
25. Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125-138.